Skip to main content

Reporter Oct 29 2021

Shifts in neuroendocrine cancer clinical trial design

Nov. 2, 2021—Clinical trials that focus on specific types of neuroendocrine neoplasms — heterogeneous tumors that can occur anywhere in the body — will be more likely to enhance drug development for these tumors, Vanderbilt physicians assert.

Read more


Breast cancer survivors: eat nuts

Nov. 1, 2021—Breast cancer survivors who reported eating nuts regularly had 50% reduced risk of breast cancer recurrence, metastasis or mortality, Vanderbilt epidemiologists found in Shanghai Breast Cancer Survival Study.

Read more


HCV infection among pregnant people increasing

Oct. 29, 2021—  by Emily Stembridge Hepatitis C virus (HCV) infection can lead to long-term health problems including liver damage, liver failure, cirrhosis, liver cancer and even death. These outcomes are especially dangerous for pregnant people and their babies. The leading cause of HCV in the U.S. is injection drug use as a result of opioid use...

Read more


Tips for a spooky and safe Halloween

Oct. 28, 2021—Vanderbilt experts offer multiple tips to help keep trick or treaters safe this Halloween.

Read more


Pancreatic beta-cell booster

Oct. 28, 2021—Blocking inflammatory signaling improves beta-cell characteristics in a mouse model of type 2 diabetes and may provide added benefits to GLP-1R diabetes medications.

Read more


The challenge of rejection

Oct. 28, 2021—Minimizing variation in how rejection is diagnosed and creating standardized surveillance protocols may help inform best practices in pediatric heart transplants.

Read more


VUMC researchers a step closer to broad ebolavirus protection

Oct. 28, 2021—  by Bill Snyder A combination of two broadly acting monoclonal antibodies isolated by researchers at Vanderbilt University Medical Center protected non-human primates from ebolavirus disease, which causes severe and often-fatal hemorrhagic fever in humans. Their findings, published this week in the journal Cell, bring closer to development the first clinical therapy effective against all...

Read more


New Vanderbilt Wound Center provides comprehensive, convenient treatment

Oct. 28, 2021—by Jill Clendening Chronic wounds impact the quality of life for an estimated 2.5% of the United States population, and because successful treatment of poorly healing wounds often requires intervention by specialists in several medical fields, Vanderbilt University Medical Center has established the comprehensive, multidisciplinary Vanderbilt Wound Center. The center, whose clinicians began seeing their...

Read more


Reid receives NRG Oncology early-stage investigator award

Oct. 28, 2021—Vanderbilt's Sonya Reid, MD, MPH, is a recipient of an NRG Oncology Underserved Minority Scholars Award.

Read more


Zost honored for research on COVID-19, other life-threatening viral diseases

Oct. 28, 2021—Vanderbilt's Seth Zost, PhD, has been awarded a major international prize for his research on COVID-19 and other life-threatening viral diseases. 

Read more


Patricia Townsend Meador Lecture

Oct. 28, 2021—Seattle Children’s Research Institute’s Douglas Diekema, MD, MPH, was at Vanderbilt last week to deliver the Center for Biomedical Ethics and Society’s Patricia Townsend Meador Lecture.

Read more


VICC’s Mayer departing to take new role with AstraZeneca

Oct. 28, 2021—Ingrid Mayer, MD, MSCI, is departing Vanderbilt University Medical Center for a new role as an executive with AstraZeneca.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more